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Abstract
Objectives—This article evaluated the drug loading, release kinetics, and matrix 
metalloproteinase (MMP) inhibition of doxycycline (DOX) released from DOX-loaded nanotube-
modified adhesives. DOX was chosen as the model drug, since it is the only MMP inhibitor 
approved by the U.S. Food and Drug Administration.
Materials and methods—Drug loading into the nanotubes was accomplished using DOX 
solution at distinct concentrations. Increased concentrations of DOX significantly improved the 
amount of loaded DOX. The modified adhesives were fabricated by incorporating DOX-loaded 
nanotubes into the adhesive resin of a commercial product. The degree of conversion (DC), Knoop 
microhardness, DOX release kinetics, antimicrobial, cytocompatibility, and anti-MMP activity of 
the modified adhesives were investigated.
Results—Incorporation of DOX-loaded nanotubes did not compromise DC, Knoop 
microhardness, or cell compatibility. Higher concentrations of DOX led to an increase in DOX 
release in a concentration-dependent manner from the modified adhesives. DOX released from the 
modified adhesives did not inhibit the growth of caries-related bacteria, but more importantly it did 
inhibit MMP-1 activity.
Conclusions—The loading of DOX into the nanotube-modified adhesives did not compromise 
the physicochemical properties of the adhesives and the released levels of DOX were able to 
inhibit MMP activity without cytotoxicity.
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Clinical significance—Doxycycline released from the nanotube-modified adhesives inhibited 
MMP activity in a concentration-dependent fashion. Therefore, the proposed nanotube-modified 
adhesive may hold clinical potential as a strategy to preserve resin/dentin bond stability.
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dental adhesive; matrix metalloproteinase; Halloysite®; doxycycline; nanotubes
Introduction
Over the past decade, resin composites have become the material of choice for direct 
restoration of teeth compromised by dental caries due to their aesthetic properties and 
minimally-invasive cavity preparations [1]. However, resin composite restorations have an 
average lifetime of only 5.7 years [2]. Secondary caries that develops at the interface 
between resin composite restoration and dental tissue (dentin/enamel) is the primary reason 
for restoration replacement [3].
Although the field of adhesive dentistry has greatly evolved over the years, the basic 
principles of bonding to tooth structure remain unchanged. It is critical to achieve a 
micromechanical interlocking (adhesive resin/tooth structure) to obtain a stable and durable 
bond [4]. This process has been termed “hybridization” or the formation of the hybrid layer 
[5]. The hybrid layer (HL) is the zone where resin monomers flow and polymerize into acid-
etched dentin to establish micromechanical interlocking with the demineralized collagen 
matrix. Unfortunately, sub-optimal resin monomer infiltration leaves behind a denuded 
collagen matrix susceptible to endogenous protease activity (i.e., matrix metalloproteinases/ 
MMPs and cathepsins) that will digest the unprotected collagen and deteriorate the HL over 
time [2, 6] and may contribute to the secondary caries formation.
In recent years, several strategies including the use of MMP inhibitors [7, 8] and chelating 
agents (e.g., chlorhexidine) [9, 10] have been suggested to counteract and/or inhibit the 
activity of MMPs and cathepsins. Yet, the levels of MMPs and/or cathepsins inhibition and 
associated bond stability was not sustained after long-term (>18 months) aging [10, 11]. 
Taken together, these findings strongly highlight the pressing need to discover a clinically-
translatable strategy that would support a localized and sustained release of MMP and/or 
cathepsin inhibitors.
Aluminosilicate (Halloysite®, HNT) is a naturally-occurring tubular clay formed by rolled 
kaolin with a general length between 500–1500 nm [12]. Interestingly, the inner surface of 
HNT has chemical properties similar to those of Al2O3 as it is formed by the octahedral 
sheet of Al–OH, while the outer surface has chemical properties identical to those of SiO2 
resulting from siloxane groups (Si–O–Si) [12]. This difference in chemical composition 
results in a negatively charged outer surface and a positively charged inner lumen 
approximately 10–15 nm in diameter [12]. With this as the goal, our group recently started 
to report on a novel strategy of modifying dental adhesives with these clay nanotubes [13–
16] to deliver MMP inhibitors (e.g., DOX) at the HL level to enhance resin-dentin bond 
durability. Our seminal proof-of-concept data clearly demonstrated e inhibition of MMP-1 
activity by eluates obtained from DOX-loaded nanotube-modified adhesives when testing 
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the effects of a 10% (w/v) doxycycline solution [14]. Our previous work lacks detailed 
information on the release kinetics, and concentration range of loaded DOX, since the MMP 
inhibition by the DOX eluate was 13.4%. The aim of this study was to further evaluate the 
loading potential and MMP-inhibiting effects of different concentrations of DOX-loaded 
nanotube-modified dental adhesives by including thorough high performance liquid 
chromatography (HPLC/mass spectroscopy) analyses to appreciate the drug loading 
potential and release kinetics. We hypothesized that increased concentrations of DOX would 
not compromise physic-chemical of the modified adhesive and would show higher release of 
DOX and MMP inhibition without toxicity.
Materials and methods
Preparation of doxycycline solutions and nanotube loading
Doxycycline hyclate (DOX, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 5 mL of 
50 mM HEPES buffer (pH = 7.2, Fisher Scientific, Pittsburgh, PA, USA) at three distinct 
concentrations (w/v): 10% (0.5 g), 20% (1 g), and 30% (1.5 g) by stirring (Fisher Thermix, 
model 310T, Fisher Scientific). The loading process started by mixing a predetermined 
amount (1.25 g) of pre-sieved (<45 µm) Halloysite® nanotubes (HNT, Dragonite 1415JM, 
Applied Minerals Inc., New York, NY, USA) in 5 mL of each DOX solution and followed by 
sonication for 2 h [19]. In order to minimize any air between and within the nanotubes, the 
solutions were placed in a vacuum (25 in.Hg) chamber for 1 h. Next, the solutions were 
mixed for 1 h and vacuum was reapplied [14]. Finally, the HNT+DOX solutions were 
centrifuged (3000 rpm) for 10 min. The supernatants were collected and stored at −20°C for 
high-pressure liquid chromatography (HPLC) analysis. Meanwhile, the HNT+DOX pellets 
were dried at 37°C, weighed, ground, and sieved.
Loading efficiency and drug loading
The amount of DOX in the supernatants (SUPs) after the loading process was assayed by 
HPLC (1100 Series, Agilent Technologies, Palo Alto, CA, USA) equipped with a UV-Vis 
detector. An Eclipse XDB-C18 (Agilent Technologies) chromatography column (3.5 µm, 
150 × 4.6 mm) and 10 µL injection volume were used. A binary mobile phase consisting of 
solvent systems A and B was used in an isocratic elution with 80:20 A:B. Mobile phase A 
was 50 mM KHPO4 in dH20 and mobile phase B was 100% acetonitrile. The HPLC flow 
rate was 1.0 mL/min and the total run time was 10 min. The retention time was 4.85 min. 
The concentration of DOX was calculated based on a standard curve of known levels of 
DOX at 273 nm. The amount of un-loaded and loaded DOX was calculated as follows:
Loading efficiency and drug loading were obtained using the equations [17]:
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Where: Da = total DOX added (g), Ds = un-loaded DOX (g), and Na = total HNT (1.25 g)
Doxycycline-loaded nanotube-modified dental adhesive fabrication
The experimental adhesives were prepared by mixing using a stirrer and conical micropestle 
[13–16]. DOX-loaded (10%, 20%, and 30% DOX) nanotubes were added to a commercially 
available adhesive (Adper Scotchbond Multi-Purpose [SBMP], 3M ESPE, St. Paul, MN, 
USA) at 15% (w/v, 75 mg of HNT+DOX in 500 µL of adhesive) and sonicated to enhance 
HNT dispersion [13–16]. Foil-covered light-proof (amber) microcentrifuge tubes were used 
during the fabrication process due to DOX photosensitivity [18]. Control groups consisting 
of unmodified adhesive (SBMP) and DOX-free nanotube modified adhesives were also 
fabricated. All specimens were prepared in a constant-temperature room (23°C) equipped 
with a filtered lighting system to lessen inadvertent polymerization.
Degree of conversion (DC)
Adhesive disks (7 × 0.24 mm, n = 5/group) were fabricated with a Teflon® mold by adhesive 
resin light-curing using a light-emitting diode curing unit (DEMI LED, Kerr, Orange, CA, 
USA). The amounts of energy applied to the specimens during light-curing for 10, 20, and 
40 s, as measured with a MARC Resin Calibrator (BlueLight analytics Inc., Halifax, NS, 
Canada) were 10.92 J/cm2, 22.49 J/cm2, and 46.18 J/cm2, respectively. DC was evaluated 
with Fourier transform infrared spectroscopy (FTIR, Jasco 4100, JASCO Corporation, 
Tokyo, Japan) in attenuated total reflection mode. The areas under 2 absorbance bands at 
1,637 cm−1 (methacrylate C=C) and 1,715 cm−1 (ester C=O) were recorded [13, 16]. DC 
was calculated using the following equation:
Knoop microhardness
Five disk-shaped (6.2 × 1.0 mm, n=5/group) adhesive specimens were prepared by light-
curing (20 s/side) for Knoop microhardness analyses. The specimens were then mounted in 
self-cure epoxy resin (EpoxiCure®, Buehler, Lake Bluff, IL, USA) and finished with 1200-
grit SiC paper (Buehler). The specimens were subjected to a microhardness test (M-400, 
LECO Corporation, St. Joseph, MI, USA) using a Knoop diamond indenter at a 50 gf load 
and 15 s dwell time [13]. Five readings at different locations were taken from each 
specimen. The long diagonal length was measured immediately and converted to a KHN 
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number (kg/mm2). The adhesive specimens used for the assays described below were 
fabricated following this protocol.
Drug release profile from DOX-loaded nanotube-modified dental adhesives
Disk-shaped specimens (n=6/group) were fabricated and individually incubated at 37°C in 1 
mL of phosphate buffer saline (PBS, pH 7.4, Fisher Scientific). Then, 150 µL aliquots (PBS 
eluates) were collected after 1, 7, 14, 21, and 28 days. An equal volume of fresh PBS was 
added back to keep the volume constant. Aliquots were stored at −20°C until used for high 
performance liquid chromatography tandem mass spectrometry (HPLC-MS-MS, Agilent 
6460 Triple Quadrupole LC/MS, San Jose, CA, USA). The analysis was performed using an 
XBridge-C18 chromatography column (3.5 µm, 100 × 2.1 mm) with a 5 µL injection 
volume. The mobile phase consisted of 0.1% formic acid in deionized water (A) and 0.1% 
formic acid in acetonitrile (B) under an isocratic condition (A:B, 80:20). A flow rate of 0.30 
mL/min was used. The mass spectrometer was operated in multi-reaction monitoring 
(MRM) mode. The transition for doxycycline was mass:charge (m/z) at 445.1 (MS1) and 
428.1 (MS2). The concentration of released DOX was calculated based on a standard curve 
prepared for DOX solution at known concentrations (r2 = 0.99986).
DOX content in the nanotube-modified dental adhesive and after long-term storage
The total DOX content in the freshly prepared adhesive disks (n=4/group) and after 4 
months of storage in PBS at 37°C was determined by dissolving the specimens in dimethyl 
sulfoxide (DMSO, Fisher Scientific). Next, the solubilized DOX-containing adhesive/DMSO 
solutions were centrifuged (4000 rpm) and the supernatants were collected and stored at 
−20°C until analyzed by mass spectrometry. The overall outcomes were to determine (1) the 
total amount of DOX that was incorporated into the adhesive specimens and (2) the amount 
of DOX remaining in each specimen after 4 months.
Antimicrobial properties of DOX-loaded nanotube-modified dental adhesives
Disk-shaped specimens (n=3/group) were fabricated and disinfected by ultraviolet (UV) 
irradiation (30 min/side) for antimicrobial analyses [14]. Streptococcus mutans (S. mutans, 
UA159) and Lactobacilli casei (L. casei, ATCC 393) were cultured aerobically in tryptic soy 
broth (Difco Laboratories, Detroit, MI, USA) for 24 h in 5% CO2 at 37°C. Then, 100 µL of 
the bacterial suspension was swabbed onto blood agar plates to individually create lawns of 
the selected bacteria [14, 19]. The agar plates were divided into zones and adhesive disks or 
10 µL of previously collected eluates were placed onto the plates (bioMérieux, Inc., 
Durham, NC, USA) [14]. The blood agar plates were incubated in 5% CO2 at 37°C. After 72 
h, the inhibition zones (mm) were measured. Chlorhexidine (0.12%) and sterile PBS were 
used as the positive and negative controls, respectively.
Cytocompatibility
UV-disinfected, disk-shaped specimens (n=4/group) were used to prepare eluates from the 
adhesives, according to the guidelines of the International Standards Organization (1993) 
[20]. The specimens were individually soaked in 15 mL of low glucose Dulbecco’s Modified 
Eagle’s Medium (DMEM, Gibco, Grand Island, NY, USA) supplemented with 10% FBS 
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(HyClone, Logan, UT, USA) and 1% penicillin–streptomycin (Sigma-Aldrich). The eluate 
extraction was performed at 37°C (24 h) under agitation. Next, the eluates were serially 
diluted to 32-fold, 64-fold, and 128-fold [21]. Human dental pulp stem cells (hDPSCs, 
AllCells LLC, Alameda, CA, USA) were cultured under standard conditions in a humidifier 
incubator (5% CO2/95% air) at 37°C in low-glucose DMEM supplemented with 10% FBS 
(HyClone) and 1% penicillin–streptomycin (Sigma). Cytotoxicity was performed as 
previously described [14] using WST-1 assay (Roche Diagnostics, Indianapolis, IN, USA) 
according to the manufacturer’s instructions. Cell viability data (%, mean ± SD) are 
presented as determined from the ratio of experimental value to value from untreated cells.
Anti-MMP activity of DOX-loaded nanotube-modified dental adhesives
The anti-MMP activity of DOX-loaded nanotube-modified adhesives was determined by 
testing eluates collected in Trishydroxymethylaminomethane (Tris) buffer over 28 days 
using a fluorescein isothiocyanate (FITC)-labeled type I collagen cleavage assay.
Eluate preparation from DOX-loaded nanotube-modified dental adhesives
Disk-shaped specimens (n=4/group) were fabricated as previously described and used to 
prepare eluates from the experimental adhesives and controls (i.e., SBMP and DOX-free 
nanotube-modified adhesive). The specimens were individually incubated at 37°C in 1 mL 
of Tris buffer (pH=7.4, 50 mM Tris-HCl, 0.2 M NaCl, 5 mM CaCl2, 1 µM ZnCl2, and 15 
mM NaN3). Aliquots (150 µL) were retrieved at days 1, 7, 14, 21, and 28. An equal volume 
of buffer was added to keep the extraction volume constant. Aliquots were stored at −20°C 
until use.
FITC labeled type I collagen cleavage assay
Type I collagen derived from rat-tail tendon (RTT) was purified and labeled with fluorescein 
isothiocyanate (FITC, Sigma-Aldrich) [22]. Human pro-matrix metalloproteinase 1 (pro-
MMP-1, 0.05 mg/mL, Abcam, Cambridge, MA, USA) was activated with 4-
aminophenylmercuric acetate (APMA, Sigma-Aldrich) [23]. Successful activation was 
confirmed using western blot analysis [24]. All the eluates (150 µL, n=4/group) collected 
from the fabricated adhesives in Tris buffer were incubated with APMA activated MMP-1 
for 30 min at RT. Then, Tris buffer (200 µL) and FITC-labeled type I collagen (50 µL) were 
added and the mixture was incubated at 37°C for 120 min. The negative and positive 
controls for the assay were Tris buffer and a 0.1% DOX solution, respectively. Samples (70 
µL) were periodically (0–120 min) removed and the reaction was terminated by the addition 
of 1,10-phenanthroline (200 mM, 10 µL) to a final concentration of 25 mM [28]. Reducing 
SDS-PAGE sample buffer was added (1:1), samples boiled for 10 min, and then resolved in 
8% SDS-PAGE (150 V, 3 h). The fluorescent signals were captured using the Bio-Rad 
imaging system (Gel Doc™ XR imaging system). The fluorescence intensity at 0 min and 
120 min incubation was analyzed with ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). The percent of FITC labeled RTT of buffer, 0.1% DOX (positive 
control), and eluate collected from the adhesives was calculated as follows [22]:
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The percent (%) of MMP inhibition was calculated using the following equation:
Transmission electron microscopy (TEM)
TEM analysis was carried out on resin composite/HNT-modified experimental adhesive 
samples in order to confirm the presence of the nanotubes (HNTs) within the adhesive resin. 
Resin composite/SBMP specimens were also prepared for comparison purposes. Disk-
shaped specimens (7 × 2 mm) were fabricated using a custom-made silicone mold (Exaflex 
Putty, GC America Inc., Alsip, IL, USA). Next, resin composite (RC, Durafill VS shade A2, 
Heraeus Kulzer GmbH, Dirmagen, Germany) was placed into the mold and cured for 40 s, 
followed by application of the nanotube-modified adhesive (DOX-free) and light-curing for 
20 s. Likewise, the control specimens were prepared using the SBMP adhesive resin. The 
specimens were cut to produce approximately 2 × 2 × 2 mm2 beams using a diamond disk 
before TEM preparation [25]. Ultra-thin sections (70–90 nm) were taken from the resin 
blocks containing the RC/adhesive samples using a diamond knife (Diatome, Electron 
Microscopy Sciences, Hatfield, PA, USA), placed on copper mesh grids and then imaged at 
80 kV (TEM, Tecnai BioTWIN, FEI, Hillsboro, OR, USA).
Statistical analysis
The data were analyzed using one-way Analysis of Variance (ANOVA) followed by Tukey’s 
test for multiple comparisons. A significance level was set at α=0.05.
Results
Loading efficiency and drug loading
Statistical analyses revealed significant (p<0.001) differences in the amount of loaded DOX, 
loading efficiency, and drug loading among the three groups (Table 1). Overall, increases in 
the concentration of DOX significantly increased the amount of DOX that was loaded into 
the HNTs. Meanwhile, increases in the concentration of DOX significantly decreased 
loading efficiency.
Degree of conversion (DC)
DC data for the control (SBMP) and modified adhesives polymerized for 10, 20, or 40 s are 
shown in Figure 1. Increasing curing times led to an increase in the DC: 61.40–64.68 % (10 
s), 64.15–68.65 % (20 s), and 70.44–73.26 % (40 s). No significant differences were found 
with each curing time among the modified adhesives and the control (SBMP, p > 0.05).
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Knoop microhardness
The Knoop microhardness values for the adhesives tested are shown in Figure 2. There were 
no significant (p > 0.05) differences between the nanotube-modified dental adhesives (with 
or without DOX) when compared to the control (SBMP).
Drug release profile from DOX-loaded nanotube-modified dental adhesives
An initial burst release was seen at day 1 and followed by a gradual decrease over time 
(Figure 3). The cumulative release of DOX (mean ± SE) from the adhesive over 28 days was 
4.04 ± 0.05 µg (10% DOX), 4.79 ± 0.07 µg (20% DOX), and 8.21 ± 0.088 µg (30% DOX). 
No significant differences in the DOX cumulative release were found among the groups (p = 
0.259).
DOX content in the nanotube-modified dental adhesive and after long-term storage
When specimen disks were dissolved in DMSO, the total DOX content in the adhesive disks 
ranged from 292.51–1644.17 µg (10–30%DOX). After long-term storage (4 months), the 
amount of DOX in the adhesive disks decreased to as low as 39.77 µg (10% DOX). The 
percent (%) remaining in the adhesive disks was 13.60 (10% DOX), 6.09 (20% DOX), and 
6.24 (30% DOX), when compared to the original amount of DOX present in the dental 
adhesives.
Antimicrobial properties
Representative photographs shown in Figure 4 demonstrate significant growth inhibition of 
S. mutans and L. casei. The inhibition zones for both bacteria when in contact with the 
DOX-loaded nanotube-modified adhesives were seen as a function of the amount of DOX 
within the adhesives. Statistical analysis showed that inhibition zones for S. mutans and L. 
casei were significant among the three groups, except for the inhibition zone of L. casei, 
which was between 10%DOX and 20%DOX.
Cytocompatibility
Figure 5 shows hDPSC viability (%) following exposure to eluates collected from the 
experimental adhesives and the control. No significant differences (p>0.05) were found 
among cells incubated with eluates, at the same dilution, for each adhesive when compared 
with the control group (i.e., cells that were not incubated with eluate, 100% survival).
Anti-MMP activity of DOX-containing eluates
FITC-labeled type I collagen cleavage assay demonstrated significant MMP-1 inhibition by 
DOX-containing eluates (Figure 6). Day 1 eluates led to the highest MMP-1 inhibition 
[16.20 ± 8.09% (10% DOX), 23.61 ± 3.33% (20% DOX), and 26.33 ± 5.01% (30% DOX)], 
followed by a gradual decrease over time. No significant differences in MMP-1 inhibition 
were found among the 10%, 20%, and 30% DOX groups (p>0.05).
Transmission electron microscopy (TEM)
Representative scanning and transmission electron micrographs of the clay nanotubes 
showed the unique hollow structure approximately 50–100 nm in width and an estimated 
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length in the range of 200–1000 nm (Figures 7A and 7B). TEM micrographs of the interface 
between RC and the nanotube-modified adhesive are shown in Figures 7C and 7D. Note the 
presence of small clusters of nanotubes (white arrows).
Discussion
Over the past decade, the body of work discussing new material- and clinical-based 
strategies to prolong the durability and overall clinical success of composite restorations 
through the use of molecules or compounds capable of inhibiting the activity of endogenous 
proteases has grown exponentially [7–11, 26]. This study provides in-depth details on the 
loading potential of doxycycline (DOX) onto aluminosilicate nanotubes and its MMP-1 
inhibition effects over time upon its release. The results of DOX loading determined by 
HPLC showed that increased concentrations of DOX significantly amplified the amount of 
loaded DOX (Table 1). Conversely, higher concentrations of DOX significantly decreased 
loading efficiency, possibly due to a threshold limit, since the amount of HNT used for 
loading was constant, regardless of the DOX concentration used. A study conducted by Qi et 
al. reported a similar trend when HNT was loaded with tetracycline [27]. Since HNT is 
positively charged on the inner surface and negatively charged on the outer surface, the 
driving force for drug loading relies on the differences in charge between the cationic DOX 
[28] and the negatively charged HNT outer surface. Results from Table 1 indicate that part 
of DOX is absorbed outside of the lumen which is approximately 10% by volume of the 
tubes and additional loaded DOX may occur in the “pockets” formed between each layer of 
these multilayer aluminosilicate clay nanotubes due to loose attachment [29]. Moreover 
when vacuum is applied, DOX may be pushed into the lumen of HNT due to negative 
pressure, regardless of the charge of the materials.
In terms of physicochemical properties, the modification of the adhesive resin with DOX-
loaded nanotubes did not compromise DC (compared within the same curing time, Figure 1) 
and microhardness (Figure 2) compared to the control (p > 0.05). These results suggested 
that even though DOX incorporation led to a darker adhesive, it did not jeopardize monomer 
conversion and also the release of DOX was not due to underpolymerized adhesive. 
Microhardness was performed since it indirectly measures DC on specimens with the same 
dimensions as those used in the drug release studies to ensure that polymerization of 
modified adhesives was not affected by specimen thickness. A strong correlation (r2 > 0.9) 
has been shown to exist between DC and microhardness [30].
The drug release profile showed an initial burst release at day 1, followed by a gradual 
decrease over time (Figure 3). Even though the release of DOX revealed an initial burst that 
may not be sustained for long term, clinically, DOX released from the modified adhesive 
would be localized at the hybrid layer where the active MMPs are present. Interestingly 
although a higher concentration of DOX (> 30%, w/v) could provide the greatest release, the 
concentration used in this study was limited by solubility and the pH of DOX. Indeed, DOX 
was not completely dissolved at concentrations higher than 30% (w/v). Moreover, the 
increased concentration of DOX significantly decreased the pH of the DOX solution (30% 
DOX pH ~ 3.5 and 50% DOX pH ~ 1). Taking into consideration that the pH of the adhesive 
resin of SBMP is approximately 3.5–4.0, the increased concentration of DOX could lead to a 
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significant pH drop upon the adhesive’s modification, which, in turn, could alter the overall 
properties of the adhesive or the adhesive/demineralized dentin interactions.
The cumulative release over 28 days was approximately 1–2% of the amount of DOX 
initially incorporated within the adhesive disks, demonstrating, for the first time, the great 
potential of Halloysite as a reservoir for loading and sustained release of distinct protease 
inhibitors. Notably, after long-term storage, the DOX left in the adhesive was approximately 
6–13% of the original concentration. In theory, most of the DOX should have either 
remained in the adhesive or released into the incubation medium. However, a portion of the 
DOX was lost during incubation. One could argue that there is a possible relationship 
between the half-life of DOX, which has been reported to be approximately 24 h in vivo or 
in cell culture conditions [31, 32]. Therefore, it would be beneficial to investigate the effects 
of other MMP inhibitors such as epigallocatechin gallate or tissue inhibitor of MMPs.
The antimicrobial properties obtained through agar diffusion tests revealed inhibition zones 
for S. mutans and L. casei when in contact with the DOX-loaded nanotube-modified 
adhesives were seen as a function of the amount of DOX within the adhesives (Figure 4). 
This indicates that DOX was successfully incorporated into the modified adhesive and 
remained active even after it was processed through the loading testing method used in this 
study. Most importantly, the eluates prepared from DOX-loaded nanotube-modified 
adhesives did not inhibit growth of either bacterial strain tested, thus indicating that the 
concentration of DOX released from the specimens was below MIC for S. mutans [0.25–
0.50 mg/mL] and L. casei [0.38–1.5 mg/mL] [33]. Furthermore, the eluates for all adhesives 
tested were considered not toxic to hDPSCs (p>0.05, Figure 5) when compared with the 
control group (i.e., cells that were not incubated with eluate, 100% survival).
Anti-MMP properties of the experimental DOX-loaded nanotube-modified adhesives were 
determined based on a FITC-labeled type I collagen assay as the substrate for MMP-1 using 
the eluates obtained from the adhesives over 28 days. MMP-1 was used since only MMP-1, 
MMP-8, and MMP-13 are true collagenases and thus cleave fibrillar collagen more 
efficiently than other MMPs. Furthermore, MMP-1 has also been found in dentin, along with 
MMP-2, MMP-3, MMP-8, and MMP-9 [34–36]. Overall, DOX-containing eluates from day 
1 showed the highest MMP inhibition (16.20–26.33%) and progressively decreased over 28 
days (Figure 6). No significant differences in the released DOX among 10%DOX, 
20%DOX, and 30%DOX were found at any time point. The degree of MMP-1 inhibition by 
DOX-containing eluates gradually decreased over time compared to the negative control 
(Tris buffer). No significant differences in MMP-1 inhibition were found among the 10%, 
20%, and 30% DOX groups (p>0.05).
The DOX mechanism of inhibition occurs through the chelation of zinc present in the 
catalytic domain of the MMPs. In this study, native/helical type I collagen derived from rat-
tail tendons was used. Worth mentioning, this assay may not provide the true degradation in 
dentin, because the demineralized dentin may be composed of both denatured and native 
type I collagen. Moreover, the accessibility of released DOX to bind with MMPs needs to be 
further investigated. Nevertheless, Toledano et al. (2012) demonstrated that DOX may 
completely block dentin MMPs for at least 4 weeks [37]. MMPs contain a zinc ion in the 
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catalytic domain and a non-exchangeable zinc ion that helps to stabilize the MMP structure. 
Moreover, MMPs also contain 2 or 3 calcium ions. The MMP inhibition of DOX may also 
occur through the binding of enzyme-associated calcium, thus changing their conformation 
and eventually resulting in inactivation of the MMPs. This may explain the long lasting and 
potent inhibition produced by DOX rather than by the sole interaction with the catalytic zinc 
[38]. Furthermore, DOX may not be suitable for bonded dentin interfaces because MMPs are 
known to participate in dentin mineralization and it has been previously reported that DOX 
will inhibit other tissue repair processes [39]. However, what remains is to determine 
whether this nonselective inhibition of enzymes by zinc/calcium chelators can adversely 
interfere with the calcification of reparative dentin.
Representative scanning and transmission electron micrographs of the nanotubes are shown 
in Figures 7A and 7B, respectively. TEM micrographs of the interface between a resin 
composite and the nanotube-modified adhesive clearly showed the presence of small clusters 
of nanotubes (Figures 7C and 7D) that was not observed in the control (Figures 7E and 7F), 
further supporting the hypothesis that nanotubes can be dispersed within the adhesive resin-
based matrix and serve as a nanocontainer for drug release, even though this study lacks 
information regarding immediate and long-term resin-dentin bond durability.
Conclusions
The current study details the loading potential and MMP inhibition of DOX released from 
the modified adhesive. Higher DOX led to higher drug loading into HNT and MMP 
inhibition in a concentration-dependent manner without altering the physicochemical 
properties of the adhesives and cytotoxicity.
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Figure 1. 
Degree of conversion (DC) of the control (SBMP) and modified adhesives that were light-
cured for 10, 20 or 40 sec. Increased curing times led to an increase in the DC values: 
61.40–64.68% (10 sec), 64.15–68.65% (20 sec), and 70.44–73.26% (40 sec). No significant 
differences were found in DC (with each curing time) among the groups (p>0.05).
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Figure 2. 
Knoop microhardness number (KHN) of the control (SBMP) and modified adhesives 
polymerized for 20 sec. KHN was 20.72 ± 1.38 (SBMP), 21.21 ± 0.59 (HNT), 22.18 ± 0.97 
(10% DOX), 21.87 ± 2.28 (20% DOX), and 20.89 ± 1.30 (30% DOX). No significant 
differences were found in Knoop microhardness among the groups (p>0.05).
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Figure 3. 
Cumulative release profile (µg, mean ± SE) of the control (SBMP) and modified adhesives 
determined by mass spectrometry. No significant differences in total cumulative DOX 
release were found among 10%, 20%, and 30% DOX (p = 0.259).
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Figure 4. 
Representative images of agar diffusion data of the control (SBMP) and modified adhesive 
disks against S. mutans (A) and L. casei (B) after 72 h of incubation. The average inhibition 
zones on S. mutans were 16.0 ± 1.1 mm (0.12% chlorhexidine, CHX), 2.3 ± 3.6 mm (10% 
DOX), 8.1 ± 0.9 mm (20% DOX), and 11.5 ± 2.6 mm (30% DOX). The average inhibition 
zones on L. casei were 14.4 ± 0.5 mm (0.12% chlorhexidine), 5.1 ± 4.0 mm (10% DOX), 7.2 
± 3.7 mm (20% DOX), and 11.3 ± 1.8 mm (30% DOX). 0.12% CHX and sterile PBS, served 
as the positive and negative controls, respectively. No inhibition zones were observed with 
specimen disks of SBMP, HNT, sterile PBS and DOX-containing eluates of all groups (data 
not shown). Statistical analysis showed that the inhibition zones on S. mutans and L. casei 
were statistically significant among 10%DOX, 20%DOX, and 30%DOX, except for the 
inhibition zone of L. casei, which was between 10%DOX and 20%DOX.
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Figure 5. 
Viability of human dental pulp stem cells (hDPSCs, %). hDPSCs were exposed to eluates of 
the control (SBMP) and modified adhesive disks. Viability of the cells incubated with 
various eluates ranged from 81.60% to 107.92% compared to that of the cells not incubated 
with eluate (100% survival). No significant differences were found among cells incubated 
with eluates of the same dilution of each group of samples, compared with cells not 
incubated with eluates.
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Figure 6. 
Inhibition of MMP-1 by DOX-containing eluates (%, mean ± SE) compared to the negative 
control (Tris buffer). MMP-1 inhibition was gradually diminished over time. Statistical 
analysis showed a significant difference between 0.1% DOX and each of the samples from 
various time points. At day 1, eluates of 30% DOX showed significantly higher MMP 
inhibition than those of the control (SBMP, p<0.05). At day 7, eluates of 10% and 30% DOX 
showed significantly higher MMP inhibition than those of control (SBMP) and HNT 
(p<0.05). No other significant differences in MMP-1 inhibition were found among other 
eluates (p>0.05).
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Figure 7. 
Scanning (A) and transmission (B) electron micrographs at 20,000× and 68,000×, 
respectively of the nanotubes (HNT, white arrows) used. TEM micrographs of the interface 
between resin composite (RC) and HNT-modified adhesive at 20,000× (C) and 120000× (D).
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Table 1
Encapsulation of doxycycline (DOX) determined by HPLC.
Group Loaded DOX (g) Loading Efficiency (%) Drug Loading* (%)
10% DOX 0.24 ± 0.00 47.48 ± 1.68 19.00 ± 0.00
20% DOX 0.36 ± 0.01 36.24 ± 0.54 29.00 ± 0.00
30% DOX 0.47 ± 0.02 31.54 ± 1.05 38.00 ± 0.01
*
Drug loading (DOX:HNT) is the ratio between loaded DOX and added HNT (1.25 g).
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